PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Aromatase”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1977

Cholesterol side chain cleavage and aromatase activities in the corpus luteum of the pregnant rhesus monkey.

Cholesterol side-chain cleavage (CSCC) and aromatase activities were measured in luteal mitochondria and tissue pieces, respectively, from rhesus monkeys on days 22, 49, 128 and 160 of gestation. CSCC activity did not vary significantly during gestation and thus probably does not respond to chorionic gonadotropin which is elevated on day 22 of pregnancy. It is not known, however, whether CSCC can be stimulated prior to day 22 when the corpus luteum is steroidogenically more active. Both 3H-pregnenolone and 3H-progesterone were synthesized from [1,2-3/]cholesterol. Aromatase activity declined from high levels on days 22 and 49 to a nadir on day 128 of pregnancy. Utilizing either [1beta-3H]androstenedione or [1beta-3H]testosterone as substrate yielded comparable results throughout gestation.

Animals↗
PubMed1978

Stabilization of placental aromatase by dithiothreitol in the presence of oxidizing agents.

Cumene hydroperoxide, sodium periodate and iodosobenzene were not able to support aromatization by placental microsomes in the absence of NADPH or molecular oxygen. In the presence of these oxidizing agents and NADPH, aromatase was slowly inactivated. Dithiothreitol (10mM) prevented the loss of aromatizing activity in the presence of these compounds. One function of dithiothreitol may be to protect aromatase by scavenging harmful oxidizing agents.

Aerobiosis↗
PubMed1979

Antifertility effects of an aromatase inhibitor, 1,4,6-androstatriene-3, 17-dione.

1,4,6-Androstatriene-3,17-dione (ATD), previously reported by us to be an aromatase (estrogen synthetase) inhibitor, was found effective in inhibiting mating and ovulation in the rat. Mating did not occur for as long as treatment was continued (up to 13 days) in 68% of the rats. In the remainder, mating and ovulation were delayed for at least 4 days past the expected day of proestrus and for an average of 5.8 days. Five animals which had been treated for 6 days mated 2 days after treatment was discontinued and all were pregnant at autopsy on day 8 of pregnancy. In contrast, when treatment was continued after mating, implantation sites were absent when the animals were examined on day 8 of pregnancy, indicating ATD may also be effective postcoitally. ATD had no significant hormonal activity in bioassay but prevented the rise in ovarian estradiol secretion on the afternoon of proestrus. Estradiol benzoate counteracted the effect of ATD when administered concomitantly, so that mating occurred at the normal time in all eight rats and ovulation occurred in six of the eight rats. The above results suggest that the aromatase inhibitor, ATD, may act in vivo to inhibit fertility by inhibition of estrogen biosynthesis.

Androstatrienes↗
PubMed1979

Subcellular distribution of aromatase in human placenta and ovary.

The aromatization of androstenedione in human ovarian microsomes is inhibited by an antibody to porcine hepatic microsomal NADPH-cytochrome c reductase. Likewise, the antibody inhibits aromatization in mitochondria isolated from human ovaries and placentae. A given quantity of the antibody produces the same percent inhibition of aromatization in microsomes and mitochondria of both ovaries and placentae. These data, in addition to the low specific activity observed for the mitochondrial aromatase, indicate that aromatization in mitochondria probably results from microsomal contamination.

Androstenedione↗
PubMed1976

Kinetic properties of human placental aromatase. Application of an assay measuring 3H2O release from 1beta,2beta-3H-androgens.

The rapid and sensitive assay of 1beta,2beta-3H-androgen aromatization by measurement of 3H2O release (Thompson, E.A., Jr., and Siiteri, P.K. (1974) J. Biol. Chem. 249, 5364-5372) has been analyzed to determine its applicability to initial rate studies. It was found that aromatization is the sole reaction catalyzed by lyophilized placental microsomes that causes a loss of tritium from position 1 or 2 of androstenedione and testosterone. Tritium is, however, removed from position 2 of the estrogen products, presumably in 2-hydroxylation, but this does not invalidate use of the assay for initial rate measurements; it was therefore used to characterize the catalytic properties of aromatase. Aromatization by the freeze-dried preparation was stimulated by K+, EDTA, and dithiothreitol, and was maximally active at pH 7.5 TO 8.0. With incubation conditions optimized for these factors, the apparent Km for NADPH is approximately 1 muM. The maximum velocity of androstenedione aromatization exceeds that of testosterone, and the affinity of the substrate binding site is higher for the former substrate, the apparent Km values being 0.1 muM and 0.4 muM, respectively. Mutual competition experiments with the androgen substrates showed that each gives simple competitive inhibition of the other's aromatization; furthermore, the apparent Ki values for each are in close agreement with their respective Km values. Androst-1,4,6-triene-3,17-dione competitively inhibits the aromatization of both androstenedione and testosterone, the apparent Ki, in both cases being 0.2 muM. It is concluded that the two androgen substrates are aromatized at a single, identical site.

Androgens↗
PubMed1977

Aromatase activity of isolated and recombined hamster granulosa cells and theca.

The major synthesis of estrogen by the follicle is postulated to require both theca and granulosa cells. Theca in this scheme provide androgens to the major aromatizing site in the follicle, and the granulosa cell. One aspect of this theory was tested here. We investigated the comparative ability of isolated granulosa and theca, alone and in recombination to aromatize androgen in vitro. We found that the granulosa aromatize [14C]substrate more efficiently than do theca, and compare with the recombined system in their ability to aromatize [14C]androgen. The data therefore substantiates one aspect of the theory regarding the nature of the synergism, i.e., that the granulosa cells, at least in vitro, are the major site of aromatization of the preovulatory follicle.

Androstenedione↗
PubMed1979

Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity.

The ability of granulosa and theca cells of the human ovarian follicle at different stages of development, as well as stromal and luteal tissues from human ovaries to metabolize androstenedione (delta 4) to testosterone (T), dihydrotestosterone (DHT), estrone (E1) and estradiol (E2) with or without exposure to additional amounts of folicle-stimulating hormone was investigated by in vitro experiments. The results show that all the aforementioned ovarian tissues metabolized delta 4 to DHT. Indeed, with the exception of estrogen-secreting granulosa cells from large antral follicle (greater than 10 mm diameter) and possibly also luteal tissue from mid-luteal phase ovaries, the various ovarian tissues preferentially metabolized delta 4 to DHT instead of E (E1 + E2). Although thecal tissue is a major source of delta 4 in human ovaries it is concluded that the granulosa cells do not interact with the theca for the synthesis of E as the follicle enlarges from 1 to 10 mm in diameter. Indeed, excessive thecal delta 4 during this growth phase probably inhibits normal follicular development. However, as the follicle enlarges beyond 10 mm in diameter, and as the granulosa cells begin to preferentially metabolize delta 4 to E, the two cell-types of the follicle may increasingly interact to enhance the follicular output of E.

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗
PubMed1977

The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.

4-Hydroxy-f-androstene-3,17-dione (4-OH-A) when tested at various concentrations was found to inhibit markedly the conversion of 4-andorstene-3,17-dione to estrogens inhuman placental and rat ovarian microsomes. To obtain evidence that estrogen biosynthesis could also be reduced in vivo with 4-OH-A, rats were treated sc at a dose level of 50 mg/kg body weight. After 3 h the ovarian veins were cannulated and blood collected. Estradiol concentrations in the plasma were reduced by 80% compared to control values during the proestrous surge and on Day 4 of pregnancy. 4-OH-A was also found to be effective in controlling estrogen-dependent reproductive and neoplastic processes. In rats treated from Day 2-7 of pregnancy, implantation of fertilized ova was completely prevented in some rats, while in others either implantation was delayed or the development of implants was retarded. 4-OH-A treatment of rats having estrogen-dependent breast tumors induced by 7,12-dimethylbenz(a)anthracene caused 80% of the tumors to regress significantly in 4 weeks of treatment; 42% of these regressed completely.

9,10-Dimethyl-1,2-benzanthracene↗